The Catalyst Brief
Emily Carter
Author

Emily Carter

Emily Carter analyzes regulatory, policy, and governance issues influencing biotechnology and medical innovation. Her work examines how regulatory decisions, legal frameworks, and public policy shape research, commercialization, and patient access. At The Catalyst Brief, Emily brings a systems-level perspective, linking policy developments with scientific and market realities.

144 articlesMostly Regulatory & Policy and Biopharmaceutical Industry

Page 11 of 12

FDA Voucher Leads to Speedy Approval of Boehringer Drug for First-Line Use in Lung CancerRegulatory & Policy

FDA Voucher Leads to Speedy Approval of Boehringer Drug for First-Line Use in Lung Cancer

The FDA's pilot program utilizing regulatory vouchers has enabled Boehringer Ingelheim to expand the indication of Hernexeos rapidly. Now approved as a first-line treatment for a challenging subset of lung cancer, this development marks an important advancement in oncology therapeutics and regulatory strategy.

Emily CarterEmily CarterFeb 27, 2026
Novo Nordisk’s CagriSema Falls Short Against Lilly’s Zepbound in Obesity Drug TrialBiopharmaceutical Industry

Novo Nordisk’s CagriSema Falls Short Against Lilly’s Zepbound in Obesity Drug Trial

In a bold move, Novo Nordisk tested CagriSema against Lilly's already established obesity medication Zepbound before regulatory approval, a rare approach signaling aggressive competitive strategy. However, the trial outcome was unfavorable for Novo’s candidate drug, impacting the company’s ambitions in the obesity treatment landscape.

Emily CarterEmily CarterFeb 23, 2026
Rainfall Health Raises $15M to Help Hospitals Navigate New CMS ModelHealthcare Investment

Rainfall Health Raises $15M to Help Hospitals Navigate New CMS Model

As the healthcare system increasingly adjusts to novel CMS payment and care delivery standards, startups like Rainfall Health are positioned to support hospitals through these transitions. Their recent $15 million funding round, led by Two Bear Capital, underscores the critical intersection of technology, policy, and hospital operations.

Emily CarterEmily CarterFeb 20, 2026
Makary, Prasad Under Fire as FDA Turmoil Reaches President TrumpRegulatory & Policy

Makary, Prasad Under Fire as FDA Turmoil Reaches President Trump

The FDA is currently navigating intense internal and external pressures as public scrutiny mounts in response to decisions affecting vaccine approvals and regulatory oversight. The involvement of President Trump signals the critical nature of these challenges for both regulatory credibility and public health policy.

Emily CarterEmily CarterFeb 20, 2026
2026 Could Mark a Turning Point for American InnovationBiotech Innovation

2026 Could Mark a Turning Point for American Innovation

Despite longstanding dominance in biotech innovation, the United States faces risks that could alter its pioneering status. This analysis explores the factors influencing this pivotal period in American innovation and the potential implications for the biotech sector.

Emily CarterEmily CarterFeb 16, 2026
AI’s Growing Impact on Pharma’s Bottom Line: Beyond Drug DiscoveryAI in Drug Discovery

AI’s Growing Impact on Pharma’s Bottom Line: Beyond Drug Discovery

While AI has been heralded for its potential in accelerating drug discovery, its immediate financial impact on major pharma firms is primarily driven by operational efficiencies and other innovative applications. Companies like Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb, and AstraZeneca exemplify this broader utilization of AI, reshaping the business of pharma.

Emily CarterEmily CarterFeb 11, 2026